Description
Humana Press Inc Protein Tyrosine Kinases From Inhibitors To Useful Drugs by Doriano Fabbro
Leading researchers, from the Novartis group that pioneered Gleevec/Glivec (TM) and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors. Part I. History and EpidemiologyObesity and Diabetes: The Historical Events Marking the Evolution of the Understanding of the Pathophysiology and Treatment of Two Related DiseasesGeorge Karanastasis and Christos S. MantzorosEpidemiology of Obesity and Diabetes: Prevalence and TrendsSusanna C. Larsson and Alicja WolkPart II. Genetics and PathophysiologyGenetics of Obesity and DiabetesDespina Sanoudou and Christos S. MantzorosNutrients and Peripherally Secreted Molecules in Regulation of Energy HomeostasisGreeshma K. Shetty, Diana Barb, and Christos S. MantzorosCentral Integration of Peripheral Signals in Regulation of Energy HomeostasisGreeshma K. Shetty, George Karanastasis, and Christos S. MantzorosRole of Energy Expenditure in Regulation of Energy HomeostasisEric S. BachmanPathophysiology of Diabetes in ObesityGeetha R. Soodini and Osama HamdyPart III. Diagnosis, Clinical Manifestations, and ComplicationsDiagnosing Obesity, Diabetes Mellitus, and the Insulin Resistance SyndromeDiana Barb and Christos S. MantzorosMetabolic SyndromeRochelle L. Chaiken and Mary Ann BanerjiObesity, Diabetes, and HypertensionAnjanette S. Tan, Stephen A. Brietzke, David W. Gardner, and James R. SowersDyslipidemia Associated With Diabetes and Insulin Resistance SyndromesJody Dushay and J. Peter OettgenObesity, Diabetes, and Endothelial DysfunctionGeetha R. Soodini, Edward S. Horton, and Osama HamdyAtherosclerosis and Peripheral Vascular Disease: Sequelae of Obesity and DiabetesSatish N. Nadig and Allen HamdanObesity, Diabetes, and Risk of Cancer: A Review of Epidemiological StudiesSusanna C. Larsson, Hans-Olov Adami, and Alicja WolkPolycystic Ovary Syndrome and Its Metabolic ComplicationsEmilia P. Liao and Leonid PoretskyObesity and Type 2 Diabetes Mellitus in Childhood and AdolescenceSusann Bluher and Wieland KiessDiabetic RetinopathyVassiliki Poulaki and Joan W. MillerObesity and Renal DiseaseAyman Geneidy and Richard SolomonDiabetic Peripheral NeuropathyRachel Nardin and Roy FreemanThe Diabetic FootThanh L. Dinh and Aristidis VevesErectile DysfunctionKenneth J. SnowInfections in Diabetes MellitusSotirios Tsiodras, Iosif Kelesidis, Christos S. Mantzoros, and Adolf W. KarchmerThe HAART-Induced Metabolic SyndromeSotirios Tsiodras, Theodoros Kelesidis, and Christos S. MantzorosPart IV. TreatmentDiet and Lifestyle in the Prevention and Management of Type 2 DiabetesFrank B. HuDiet, Exercise, and Behavioral Treatment of ObesityGeorge L. BlackburnMedical Approaches to Treatment of the Obese PatientGeorge A. Bray and Donna H. RyanMedical Treatment of the Obese Patient With Type 2 DiabetesJean L. Chan, Christos S. Mantzoros, and Martin J. AbrahamsonSurgical Treatment of Obesity and DiabetesBenjamin E. Schneider and Edward C. MunFuture Developments in the Area of Pharmacotherapy: Molecules in Early-Stage Preclinical Development and in Clinical Trials That May Affect Energy HomeostasisDiana Barb, Greeshma K. Shetty, and Christos S. MantzorosIndex